Unchanged renal haemodynamics following high dose ascorbic acid administration in normoalbuminuric IDDM patients.
The object of the study was to test whether high dose ascorbic acid (AA) could normalize glomerular hyperfiltration in insulin-dependent diabetes mellitus (IDDM) patients. A prospective, double-blind, randomized, placebo (tartaric acid, TA) controlled study design was used, with parallel treatment lasting 4 weeks. Measurements were made before and after treatment, on 24 normoalbuminuric, normotensive male IDDM patients, who were randomized to ascorbic acid (n = 12, age 35 years (18-39), diabetes duration 12 years (2-12), BP 128/82 mmHg (SD 14/6)), or to placebo (TA) (n = 12, age 30 years (19-36), diabetes duration 8 years (2-17), BP 119/75 mmHg (SD 9/7). The intervention consisted of 6 enterosoluble tablets of 500 mg AA or 213 mg TA, twice a day, being daily doses of 6 g AA or 2.55 g TA. No significant differences in any of the parameters measured were seen, when comparing results following AA or placebo treatment. The glomerular filtration rate (GFR, clearance of 125I-iothalamate) was unchanged while effective renal plasma flow (ERPF, clearance of 131I-hippuran) tended to decline in both groups. The GFRs before and after treatment in the AA-treated group were 141 (SD 15) and 134 (SD 12) ml min-1 1.73 m-2; NS (2p = 0.09). In the TA-treated group they were 142 (SD 19) and 137 (SD 16) ml min-1 1.73 m-2; NS (2p = 0.20). The ERPFs in the AA group were 584 (SD 93) and 545 (SD 47) ml min-1 1.73 m-2; (2p = 0.06). In the TA group they were 618 (SD 108) and 574 (SD 98) ml min-1 1.73 m-2 (2p = 0.03). The filtration fractions (FFs) in the AA group were 0.244 and 0.246 NS.(ABSTRACT TRUNCATED AT 250 WORDS)
Klein
F
F
Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus Kommunehospital, Denmark.
Juhl
B
B
Christiansen
J S
JS
D000293:Adolescent; D000328:Adult; D001205:Ascorbic Acid / Q000008:administration & dosage* / Q000494:pharmacology; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D004311:Double-Blind Method; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology*; D008297:Male; D017596:Renal Plasma Flow, Effective / Q000187:drug effects*; D013644:Tartrates / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects
D001786:Blood Glucose; D013644:Tartrates; D001205:Ascorbic Acid; C029768:tartaric acid